Current Headlines

  1. Sosei Subsidiaries Heptares To Acquire G7 Therapeutics To Extend Leadership In GPCR-Focused Drug Discovery And Development

    Sosei Group Corporation recently announces that Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, has signed a share purchase agreement that will allow the acquisition of 100% in G7 Therapeutics, a privately held drug discovery and development company based in Switzerland, for CHF 12 million cash

  2. Boehringer Ingelheim And China Southeast University Collaborate To Develop New Treatment Approaches For Hearing Loss

    Boehringer Ingelheim and China Southeast University Institute of Life Sciences recently announced the start of a joint research project to develop new treatment approaches for hearing loss through regeneration of hair cells from inner ear stem cells

  3. Enamine And Pcovery Extend Drug Discovery Collaboration

    Enamine Ltd., a chemical company, producer of building blocks and screening libraries, and Danish biotech company Pcovery, have announced that they have extended their collaboration for the discovery of new drugs for the treatment of invasive fungal infections and platform technology development

  4. Alzheon To Present New Clinical Data And Analyses For ALZ-801, An Amyloid-Targeted Drug Candidate, And Its Active Molecule Tramiprosate At The 9th Clinical Trials On Alzheimer’s Disease Congress

    Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, recently announced that the company will be making two presentations at the 9th Annual Clinical Trials on Alzheimer’s Disease (CTAD) congress in San Diego, California, to be held on December 8-10, 2016

  5. Rosetta Genomics Enters Research Collaboration Using microRNA Biomarkers To Predict Response To Leading Immuno-Oncology Drug Nivolumab In Lung Cancer Patients

    Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab, an immunotherapy drug marketed as Opdivo, which is approved for the treatment of lung cancer patients

  6. Ra Pharmaceuticals Receives Orphan Drug Designation In The European Union For RA101495 For Treatment Of Paroxysmal Nocturnal Hemoglobinuria

    Ra Pharmaceuticals , a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, recently announced that the European Commission has designated RA101495 as an orphan medicinal product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)

  7. New Pre-Clinical Data On A vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease To Be Presented At The Society For Neuroscience 2016 Meeting In San Diego

    vTv Therapeutics Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, recently announced that Dr. Bobby Thomas, Associate Professor at Medical College of Georgia, Georgia Regents University at Augusta, will present a poster at the Society for Neuroscience 2016 meeting in San Diego, featuring new pre-clinical data on a vTv small molecule drug candidate against Parkinson’s disease (PD)

  8. Bristol-Myers Squibb And Enterome Announce Immuno-Oncology Collaboration Focused On Microbiome-Derived Biomarkers, Drug Targets And Bioactive Molecules

    Bristol-Myers Squibb Company and Enterome, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer.

  9. Enanta Pharmaceuticals Announces AbbVie’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease

    Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response following 12 weeks of treatment (SVR12) with AbbVie’s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in the primary intent-to-treat (ITT) analysis

  10. Bertin Pharma And INDIGO Biosciences Sign Agreement For Distributing Nuclear Receptor Assay Kits In Europe

    Over 40 product references to assay nuclear receptors are now available for European researchers during their work in drug discovery and toxicology